Target intelligence / Profile preview

O-antigen polysaccharide and Vi capsular polysaccharide of Salmonella (anti-Salmonella antibody targets)

Molecular classification
Polysaccharide antigen, Bacterial surface antigen, Group IV capsule (for O-antigen capsule)[3], Capsular polysaccharide (for Vi antigen), Other
01

Overview

O-antigen polysaccharide and Vi capsular polysaccharide are major surface carbohydrate antigens of Salmonella species, functioning as critical immune targets and virulence factors. The O-antigen polysaccharide forms the serotype-defining outer part of lipopolysaccharide (LPS), composed of repeating oligosaccharide units with high structural variability that determine immunogenic specificity and resistance to host complement-mediated killing[1][5][7]. Vi capsular polysaccharide, present in Salmonella Typhi and Paratyphi C, is a distinct extracellular capsule that shields surface antigens and is a major target of protective antibodies in typhoid vaccines[1][6]. Both antigens are exploited in vaccine strategies—either as purified polysaccharides or conjugated to carrier proteins—to stimulate production of anti-Salmonella antibodies that mediate protection via opsonization, complement activation, and immune memory[6][7]. Variability in O-antigen structure among Salmonella serovars and the limited immunogenicity of unconjugated polysaccharides present challenges for vaccine development[8][1]. These bacterial polysaccharide antigens are not conventional receptors or enzymes but are validated immunological targets for prophylactic (vaccine) interventions. **Note:** This entry is marked as **is_incorrect: true** because it describes not a single molecule/receptor, but an immunological concept (antibody production targeting two different polysaccharide antigens), and includes more than one canonical target; structured information requires treatment as two entities or as a vaccine concept, not a discrete molecular target[1][6][7].

Other names
O-antigen polysaccharideO-polysaccharide antigenLipopolysaccharide O-antigenVi capsular polysaccharideVi antigen
02

Mechanism of action

Antibodies targeting these antigens mediate opsonization and phagocytosis, promote complement-mediated bactericidal activity, prevent bacterial attachment/invasion, and establish immunological memory via an adaptive immune response[4][6][7].

03

Biological functions

Immune response (elicits production of protective antibodies)Evasion of immune recognition (key virulence factor in Salmonella)[3][7]Host-pathogen interaction/surface antigenicity[3][7]Resistance to complement-mediated killing[7]Other
04

Disease associations

Infection (Salmonellosis, typhoid fever, paratyphoid fever, invasive nontyphoidal Salmonella[iNTS] disease)[8][6]Other
05

Safety considerations

Immune cross-reactivity between serogroups (may limit coverage or cause off-target effects)[8]Polysaccharide antigens generally less immunogenic in infants and young children unless conjugated to proteinsVariation in O-antigen structure across different serovars/strains may limit broad protection and complicate vaccine design[1][8][9]Rare risk of reactogenicity/allergy with polysaccharide vaccines
06

Interacting drugs

Typhoid polysaccharide vaccines (Vi polysaccharide vaccines)[6]

2 more in the full profile.

07

Biomarkers

Anti-Vi IgG antibody titer (for Vi-containing vaccines)[6]Anti-O-antigen IgG/IgM titer[4][7][8]Bactericidal antibody levels

Beyond the preview

Go deeper on O-antigen polysaccharide and Vi capsular polysaccharide of Salmonella (anti-Salmonella antibody targets).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on O-antigen polysaccharide and Vi capsular polysaccharide of Salmonella (anti-Salmonella antibody targets).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call